Salvage therapeutic strategies for bacillus Calmette–Guerin failure

@article{Hassler2019SalvageTS,
  title={Salvage therapeutic strategies for bacillus Calmette–Guerin failure},
  author={Melanie R. Hassler and Shahrokh Francois Shariat and Francesco Soria},
  journal={Current Opinion in Urology},
  year={2019},
  volume={29},
  pages={239–246}
}
Purpose of review To give an overview of current options for conservative treatment of patients failing intravesical bacillus Calmette–Guerin (BCG) and to discuss emerging approaches with potential future clinical applications. Recent findings Radical cystectomy is the standard-of-care for patients failing BCG therapy. In patients unfit or unwilling to undergo surgery, salvage therapy options could be proposed with the aim to offer local cancer control and prevent progression to muscle-invasive… 
Therapeutic management of Bacillus Calmette–Guerin refractory patients: a narrative review
High risk bladder cancer (BC) patients who fail Bacillus Calmette–Guerin (BCG) therapy suffer from a challenging disease due to its molecular and clinical heterogeneity. The course of the disease
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer
TLDR
This review presents the topics of BCG unresponsive NMIBC; definition, prognosis, and further treatment options: immunotherapy, intravesical chemotherapy, gene therapy, and targeted individualized therapy.
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration
TLDR
Patients who underwent initial BST for BCG-unresponsive NMIBC, rates of treatment failure were very high, and patients who underwent delayed cystectomy after ≥2 lines of BST had elevated rates of extravesical disease.
Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
TLDR
Preoperative serum AGR levels independently predicted the risk of disease progression in patients with non-muscle-invasive bladder cancer and was not found to be associated with either RFS or PFS in NMIBC patients based on their EAU risk group.
[Improvement of vaccination activities in urology].
TLDR
The importance of various aspects of vaccinations in urology are highlighted and the improvement of consultation techniques for vaccinations is focused on to increase the vaccination rate and acceptance in the future.
NFκB-Activated COX2/PGE2/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
TLDR
It is observed that BCG non-selectively induces both CTL-attracting chemokines and Treg/MDSC attractants and suppressive factors in human BlCa tissue explants, in a mechanism involving NFκB-induced PGE2 synthesis and EP4 signaling.
Verbesserung der Impftätigkeiten in der Urologie
Effektive Impfstoffe gegen verschiedene urologisch wichtige Erkrankungen stehen seit Langem zur Verfügung, und dennoch sind generell die Impfaktivitäten in der Urologie unzureichend präsent. Folglich
...
...

References

SHOWING 1-10 OF 64 REFERENCES
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer
TLDR
A more in-depth report of the therapeutic strategy with sequential gemcitabine and docetaxel intravesical therapy for this treatment-refractory population and practical advice on the approach to this challenging patient population is provided.
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
TLDR
The potential for synergistic antitumour activity of interferon (IFN)-alpha (α) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy.
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
TLDR
Valrubicin was effective and well tolerated in patients with carcinoma in situ of the bladder refractory to BCG therapy and delaying cystectomy while attempting salvage therapy with valRubicin does not pose an undue risk to most patients.
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
  • G. Dalbagni, P. Russo, D. Bajorin
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Gemcitabine has activity in a high-risk patient population and remains a viable option for some patients who refuse cystectomy and has been found to be effective in patients with superficial bladder cancer refractory or intolerant to intravesical BCG therapy.
...
...